GEN Exclusives

More »

GEN News Highlights

Back to Item »

BioMarin Buys ZyStor for $22M Up Front to Pad ERT Pipeline and Enzyme Delivery IP

Firm claims ZyStor’s late-preclinical Pompe disease product will cost less to develop than its own.

Forward this item to a colleague:


(Separate multiple addresses by commas)


(Separate multiple addresses by commas)


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »